Table 1.
Clinical data and demographics corresponding to urine samples from subjects with or without G2019S-LRRK2 mutations, with or without PD
| LRRK2+/PD- | LRRK2+/PD+ | LRRK2-/PD+ | LRRK2-/PD- | p valuea | |
|---|---|---|---|---|---|
| Gender M(F) | 29(30) | 8(18) | 23(16) | 2(6) | ns |
| Age | 60 (52-66) | 59 (53.75-70.25) | 59 (53-63) | 60.5 (56-75) | ns |
| Age at onset | NA | 55 (47-60.25) | 55 (50-60) | NA | ns |
| LEDD | NA | 500 (400-650) | 300 (0-600) | NA | ns |
| UPDRS_III | 4 (0-6) | 19.5 (15.75-22.25) | 19 (16.5-24) | 0 (0-0) | <0.0001 |
| MoCA | 26 (26-29) | 26 (25-27) | 28 (26-28) | 27 (<26-30) | ns |
| H&Y | 0 (0-0) | 2 (2-2.5) | 2 (2-2) | 0 (0-0) | <0.0001 |
LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (gender and MoCA), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)